Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player


IBT's principals, Dr. M. Javad Aman and Dr. Kelly Warfield have a long track record of scientific and developmental accomplishments in vaccine and immunotherapeutics development for infectious diseases, including highly productive work during their tenures at USAMRIID. The company has a successful track record in early-stage discovery work for viral and bacterial diseases, including discovery of antimicrobial small molecule inhibitors, development of antibody therapeutics for Marburg virus (collaboration with Scripps), development of a panfilovirus VLP-based vaccine (NIAID) as well as a second generation filovirus vaccine (Collaboration with University of Texas) and numerous other projects. Over the past four years IBT has secured and managed over $35M in government grants and contracts.

Dr. M. Javad Aman
President and CSO

Dr. M. Javad Aman received his Ph.D. in molecular immunology at the University of Mainz, Germany. Following a research fellowship at the NIH and an academic position at the University of Virginia, he worked as a lead scientist at USAMRIID for 7 years prior to founding Integrated BioTherapeutics (IBT). His research at USAMRIID resulted in development of a vaccine for Ebola and Marburg viruses, now in late pre-clinical development. His work has also led to small molecule inhibitors of filoviruses currently in development by Functional Genetics Inc. under a DTRA funded program, as well as human therapeutic antibodies for Staphylococcal Enterotoxin B, currently funded by NIAID and under development at IBT. Dr. Aman is currently the President and Chief Scientific Officer at IBT and serves as PI on multiple government funded contracts and grants. He has authored over 60 publications in international journals and is the inventor on multiple U.S. and international patents and patent applications.

Dr. Kelly Lyn Warfield
Vice President of Vaccine Development

Dr. Warfield has been working in immunology, preclinical and advanced vaccine, therapeutic, and animal model development for over 19 years. Her personal work has focused on rotavirus, Norwalk, Lassa, Ebola and Marburg virus-like particles. For 5 years during her tenure at USAMRIID, she was responsible for 3 multi-million dollar subcontracts for screening and development of lead therapeutics for hemorrhagic fever viruses. The projects involved screening thousands of chemical, antisense, and siRNA compounds using in vitro and in vivo models of filoviruses and arenaviruses. Additionally, for more than 10 years, she has been the technical lead for the development of the filovirus VLP vaccines including winning, maintaining, and implementation of funding at USAMRIID in the laboratory of Dr. Sina Bavari. She has been responsible for conducting the biochemical characterization, process development, and animal efficacy studies on filovirus vaccines. Dr. Warfield was trained at the National Institute of Standards and Technologies, the National Cancer Institute, Loyola College in Maryland, and Baylor College of Medicine. She is an author on over 50 peer reviewed publications and an author of multiple U.S. patents and patent applications related to viral vaccines and therapeutics.